ApTOLL, a TLR4 modulator aptamer, has demonstrated cerebroprotective effects in a
permanent ischemic stroke mouse model, as well as safety and efficacy in early phase …

In the reperfusion era, a new paradigm of treating patients with endovascular treatment
(EVT) and neuroprotective drugs is emerging as a promising therapeutic option for patients …

Since Toll-like receptor 4 (TLR4) mediates brain damage after stroke, development of TLR4
antagonists is a promising therapeutic strategy for this disease. Our aim was to generate …

Importance ApTOLL is a TLR4 antagonist with proven preclinical neuroprotective effect and
a safe profile in healthy volunteers. Objective To assess the safety and efficacy of ApTOLL in …

ApTOLL is an aptamer that antagonizes Toll-like receptor 4 and improves functional
outcomes in models of ischemic stroke and myocardial infarction. The aim of this study was …

Treatment of acute ischemic stroke with intravenous tissue-type plasminogen activator is
underutilized partly due to the risk of life-threatening hemorrhage. In response to the clinical …

Stroke is a major cause of death and disability across the world, and its detrimental impact
should not be underestimated. Therapies are available and effective for ischemic stroke (eg …

Purpose Odatroltide (LT3001), a novel small synthetic peptide molecule designed to
recanalize occluded blood vessels and reduce reperfusion injury, is safe and efficacious in …

Cell specific-targeted therapy (CSTT) for acute ischemic stroke remains underdeveloped.
Cerebrovascular endothelial cells (CECs) are key components of the blood–brain barrier …

Toll-like receptors (TLRs) are central sensors for the inflammatory response in ischemia-
reperfusion injury. We therefore investigated whether TLR4 inhibition could be used to treat …